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Abstract
Objective: The Philadelphia (Ph) chromosome, consisting of the t(9;22)(q34;q11) translocation, is 
observed in ~90% of patients with chronic myeloid leukemia (CML). Variant Ph translocations are 
observed in 5%-10% of CML patients. In variant translocations 3 and possibly more chromosomes are 
involved. Herein we report 6 CML patients with variant Ph translocations.
Materials and Methods: Bone marrow samples were examined using conventional cytogenetic meth 
ods.  Fluorescence  in  situ  hybridization (FISH)  with  whole-chromosome paints  and  BCR-ABL  1D 
probes were used to confirm and/or complement the findings, and identify rearrangements beyond the 
resolution of conventional cytogenetic methods. 
Results: Variant Ph translocations in the 6 patients were as follows: t(7;22)(p22;q11), t(9;22;15)
(q34;q11;q22), t(15;22)(p11;q11), t(1;9;22;3)(q24;q34;q11;q21), t(12;22)(p13;q11), and t(4;8;9;22)
(q11;q13;q34;q11).
Conclusion: Among the patients, 3 had simple and 3 had complex variant Ph translocations. Two of 
the presented cases had variant Ph chromosomes not previously described, 1 of which had a new com-
plex Ph translocation involving chromosomes 1, 3, 9, 22, and t(1;9;22;3)(q24;q34;q11;q21) apart from 
a clone with a classical Ph, and the other case had variant Ph translocation with chromosomes 4, 8, 9, 
and 22, and t(4;8;9;22)(q11;q13;q34;q11) full complex translocation. Number of studies reported that 
some patients with variant Ph translocation were poor responders to imatinib. All of our patients with 
variant  Ph  translocations  had  suboptimal  responses  to  imatinib,  denoting  a  poor  prognosis  also. 
Variant Ph translocations may be important as they are associated with prognosis and therapy for CML 
patients. (Turk J Hematol 2011; 28: 186-92)
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Chronic  myeloid  leukemia  (CML)  is  a  clonal 
myeloproliferative neoplasm arising from neoplas-
tic  transformation  of  a  pluripotent  stem  cell.  The 
Philadelphia (Ph) chromosome, which is the result 
of  t(9;22)(q34;q11),  is  observed  in  ~90%  of  CML 
patients.  The  translocation  leads  to  fusion  of  the 
proto-oncogene  Abelson  (ABL)  and  a  particular 
DNA sequence known as breakpoint cluster region 
(BCR), thereby giving rise to 2 new chimeric genes 
5’ ABL-3’ BCR on the derivative chromosome 9 and 
5’ BCR-3’ ABL on the derivative chromosome 22. 
Variant  Ph  translocations  have  been  observed  in 
5%-10% of CML patients [1]. These variant translo-
cations may be simple or complex. Simple variant 
translocations occur when the deleted segment of 
22q is translocated onto a chromosome other than 
chromosome  9.  In  complex  translocations,  3  and 
possibly more chromosomes are involved [2,3]. In a 
few cases of variant Ph translocations the BCR-ABL 
fusion gene is located on chromosomal sites other 
than 22q11 [4].
More than 1 mechanism plays a role in the evolu-
tion of variant Ph translocation; it can originate sec-
ondary to simple Ph translocation or can arise simul-
taneously in a 3-way rearrangement. Different mech-
anisms involved in the formation of a variant translo-
cation  may  have  different  clinical  implications:  a 
2-step evolution might resemble a clonal evolution, 
whereas variant translocations that evolve simulta-
neously in a 3-way rearrangement may be similar to 
simple Ph translocation [5]. The clinical significance 
of variant t(9;22) translocations is not clear [4].
In the present study bone marrow samples from 
6 CML patients were examined using conventional 
cytogenetic  methods,  FISH  with  whole-chromo-
some paints, and BCR-ABL 1D probes to confirm 
and/or complement the findings, and identify rear-
rangements beyond the resolution of conventional 
cytogenetic  methods.  Additionally,  2  of  the  CML 
patients had new complex translocations; 1 between 
chromosomes 1, 3, 9, 22, and other between 4, 8, 9, 
and 22. Possible correlations between chromosome 
breakpoints other than 9 and 22 in these Ph variant 
tranlocations, and recent updates for the map loca-
tions of consistent cancer breakpoints, fragile sites, 
and oncogenes are discussed.
Materials and Methods
Patients
The study included 6 clinically diagnosed CML 
patients that were referred for cytogenetic analysis 
and had variant Ph translocations. Clinical features 
of the patients are shown in Table 1.
Özet
Amaç: t(9;22)(q34;q11) sonucu oluşan Philadelphia (Ph) kromozomu, kronik miyeloid lösemi (KML) 
olgularının %90’ dan fazlasında gözlenir. KML hastalarının %5-10 unda varyant Ph translokasyonları 
bulunur. Varyant translokasyonlar üç ve daha fazla kromozom içerebilmektedir. Bu çalışmada varyant 
Ph translokasyonlu 6 KML olgusu sunulmaktadır.
Yöntemler ve Gereçler: Kemik iliği örnekleri konvansiyonel sitogenetik kullanılarak incelendi; BCR-
ABL 1D problarının kullanıldığı Floresan İn Situ Hibridizasyon (FISH) yöntemi bulguların doğrulan-
ması ve konvansiyonel sitogenetik yöntemlerinin tespit etmekte yetersiz kaldığı yeniden düzenlemele-
rin tanımlanması amacıyla uygulandı. 
Bulgular: Çalışmada yer alan 6 hastanın varyant Ph translokasyonları: t(7;22)(p22;q11), t(9;22;15)
(q34;q11;q22),  t(15;22)(p11;q11),  t(1;9;22;3)(q24;q34;q11;q21),  t(12;22)(p13;q11)  ve  t(4;8;9;22)
(q11;q13;q34;q11) dır.
Sonuç: Üç olguda basit, 3 olguda ise karmaşık (kompleks) varyant Ph translokasyonları saptamış 
bulunuyoruz. Olgularımızın ikisi daha önce bildirilmeyen varyant Ph kromozomları taşıyorlardı. Bu 
olgulardan biri klasik Ph’lı bir klonun yanısıra 1, 9, 22 ve 3 numaralı kromozomları içeren t(1;9;22;3)
(q24;q34;q11;q21) formüllü yeni bir kompleks Ph translokasyonuna; diğeri ise 4, 8, 9 ve 22 numaralı 
kromozomları içeren t(4;8;9;22)(q11;q13;q34;q11) kompleks translokasyonlu varyant Ph’ya sahipti-
ler. Varyant Ph’lı 6 olgunun tümü kötü prognoza işaret eden yetersiz imatinib cevabı gösterdiler. 
(Turk J Hematol 2011; 28: 186-92)
Anahtar kelimeler: Kronik myeloid lösemi (KML), varyant Philadelphia kromozomu, sitogenetik, 
floresan in situ hibridizasyon (FISH)
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Bone marrow (BM) samples were used for cyto-
genetic and FISH analysis.
Cytogenetics
Cytogenetic  analysis  was  performed  on  over-
night and 24-h unstimulated BM cultures using stan-
dard  procedures.  The  GTL  (G-bands  via  trypsin 
using Leishman) banding technique [6] was applied 
to the slides, karyotypes were described according 
to the International System for Human Cytogenetic 
Nomenclature  (2005)  [7],  and  15-20  metaphases 
were analyzed for each sample. 
FISH analysis
Fresh slides were used for FISH analysis. Before 
hybridization the slides were pre-treated with pep-
sin,  followed  by  post-fixation  and  denaturation. 
FISH  analysis  was  performed  according  to  the 
manufacturer’s  protocols.  BCR-ABL1  rearrange-
ment  was  examined  using  a  BCR-ABL1  D-FISH 
probe (BCR: 500 Kb in red; ABL1: 600 Kb in green; 
Oncor, Inc., Gaithersburg, MD, USA). 
FISH analyses using whole chromosome paint 
(WCP) probes to characterize only complex vari-
ant  translocations  in  patients  2,  4  and  6.:  for 
patient 2 painting probes for chromosomes 15 and 
22 were digoxigenin labeled (WCP 15 and WCP 
22; Oncor, Gaithersburg, MD, USA); for patient 4 
painting  probes  for  chromosomes  1,  9,  and  22 
(WCP 1, 9, and 22; XCP-MetaSystems); for patient 
6 painting probes for chromosomes 4, 8, 9, and 22 
(WCP  4,  8,  9,  and  22;  XCP-MetaSystems  and 
Cytocell).  Fluorescence  microscopy  was  per-
formed with a Nikon E600 microscope with a tri-
ple-pass  filter  and  a  cooled  monochrome  CCD 
camera,  using  MacProbe  FISH  analysis  software 
and a CytoVision Ultra system (Applied Imaging, 
Pittsburgh, PA). 
Results
Variant Ph translocations were identified in all 6 
patients using G-banding analysis, and were con-
firmed via FISH analysis. G-banding and FISH results 
are shown in Table 2. 
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Table 1. Clinical features of the patients
Case   1  2  3  4  5  6
Age/Sex  39/F  23/M  52/M  33/F  60/F  32/M
Reason for referral  CML  CML  CML  CML   CML  CML
Splenomegaly   0  NA  0  15   0  25
(cm below the costal margin) 
Hemoglobin level (g/dL)  9.7  NA  13.9  9,7  11  8,4
Platelet count (mm3)  360  NA  220  360  180  214
Leukocyte count (mm3)  75.4  NA  67.7  160  69,7  123,7
Blasts in PB (%)  1  NA  0  1  0  3
Sokal score  Low  NA  Low  Intermediate  Low  High
Best cytogenetic response  PCR  NA  CCR  NCR  NCR  NCR
Treatment   HU, IFN, IM  NA  HU, IFN,I M  HU, IFN, ARA-C, IM, D  HU, GL  HU, IM, D
NA: Not Available; F: Female; M: Male; PB: Peripheral Blood; HU: Hydroxyurea; INF: Interferon; ARA-C: Cytosine arabinoside; IM: Imatinib mesylate; D: Dasatinib;
PCR: Partial cytogenetic response; CCR: Complete cytogenetic response; NCR: No cytogenetic response
Table 2. G-Banding and FISH results in the patients
Patient  Karyotype  Probe  Hybridization 
      pattern
1  46,XX,t(7;22)(p22;q11)  BCR-ABL1   BCR-ABL (+)
    D-FISH 
2  46,XY,t(9;22;15)  WCP 15 and 22  confirmed
  (q34;q11;q22)   
3  46,XY,t(13;15)(p11;q13),  BCR-ABL1  BCR-ABL (+)
  t(15;22)(p11;q11)  D-FISH 
4  46,XX,t(9;22)(q34;q11)/  BCR-ABL1  BCR-ABL
  46,XX,t(1;9;22;3)  D-FISH  (+),
  (q24;q34;q11;q21)   WCP 1, 9, 22  confirmed
5  46,XX,t(12;22)(p13;q11)  BCR-ABL1   BCR-ABL (+)
    D-FISH 
6   46,XY,t(4;8;9;22)  BCR-ABL1  BCR-ABL
  (q11;q13;q34;q11)  D-FISH  (+),
    WCP 4, 8, 9,   confirmed
    and 22   Cytogenetics
In all, 3 of the patients (1, 3, and 5) had simple 
variant Ph translocations and 3 (2, 4, and 6) had 
complex translocations. Among the complex vari-
ant  Ph  translocations,  3  chromosomes  were 
involved in 1 patient (2) and 4 chromosomes were 
involved in 2 patients (4 and 6). Clonal evolution 
was observed only in patient 4; there were 2 clones 
1  with  a  classical  Ph  and  1  with  t(1;9;22;3)
(q24;q34;q11;q21).  The  chromosomal  breakpoints 
of  the  variant  Ph  translocations  were  1q24,  3q21, 
4q11, 7p22, 8q13, 12p13,15p11, and 15q22. In patient 
3  additional  clonal  chromosomal  changes  along 
with  variant  Ph  translocation  were  observed 
[t(13;15)(p11;q13)].  Partial  G-banding  karyotypes 
are presented in Figure 1.
 
FISH analysis
In 5 patients (1, 3, 4, 5, and 6) dual-color FISH 
with the use of the BCR and ABL probes showed the 
BCR-ABL fusion gene on the Ph chromosome. In 
patient 2 BCR and ABL probes could not be used 
due to insufficient material. With the WCP probes 
involvement of chromosomes other than 9 and 22 in 
the complex variant translocations were confirmed 
in patients 2, 4, and 6. FISH images are shown in 
Figure 2. 
Discussion 
In the present study chromosomal breakpoints 
of the variant Ph translocations other than classical 
9 and 22 breakpoints were 1q24, 3q21, 4q11, 7p22, 
8q13,  12p13,15p11,  and  15q22.  All  8  breakpoints 
observed in the 6 patients are listed as variant Ph 
translocations  in  the  Mitelman  database  (http://
www.cgap.nci.nih.gov/Chromosomes/Mitelman; 
updated 23 February 2009) [8]. Among the chromo-
somes that constituted variant Ph translocations in 
the presented patients, those that were previously 
described are shown in Table 3.
It was reported that breakpoints involved in vari-
ant Ph translocations are primarily located in light-
staining bands [2]. Apart from 1q24, the breakpoints 
observed  in  the  present  study  were  also  in  light-
staining bands. Most of the breakpoints observed in 
the present study harbor genes known to be associ-
ated  with  neoplasia.  GPA33  in  1q24,  DIRC2  and 
HSPBAP1 in 3q21, BTL in 4q11, ETV6 in 12p13, and 
PML in 15q22 genes are implicated in different leu-
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Figure 1. Partial G-banding karyotypes in the 6 patients. A. Patient 
1: t(7;22)(p22;q11). B. Patient 2: t(9;22;15)(q34;q11;q22). C. Patient 
3:  t(15;22)(p11;q11)  and  clonal  chromosomal  changes  t(13;15)
(p11;q13). D. Patient 4: t(1;9;22;3)(q24;q34;q11;q21). E. Patient 5: 
t(12;22)(p13;q11). F. Patient 6: t(4;8;9;22)(q11;q13;q34;q11)
Figure  2. FISH analysis results. A. Signals of BCR-ABL fusion on 
interphase cells via the BCR-ABL1 D-FISH probe (ONCOR). Green 
signals on 1 of chromosome 9, red signals on 1 of chromosome 
22, and yellow signals on the Ph chromosome showing BCR-ABL 
fusion. B. In patient 2 metaphase FISH showing t(9;22;15) via WCP 
15 (ONCOR) red signals. C. In patient 4 metaphase FISH showing 
t(1;9;22;3) via WCP 1, 9, and 22 (MetaSystems). CI. Chromosome 
1 is green and chromosome 22 is red. CII. and chhromosome 9 is 
green and chromosome 22 is red. D. In patient 6 metaphase FISH 
showing t(4;8;9;22) via WCP 4 and 8, (Cytocell), and WCP 9 and 22 
(MetaSystems). DI. Chromosome 4 is green and chromosome 8 is 
red. DII. Chromosome 4 is green and chromosome 22 is red. DIII. 
Chromosome 8 is red and chromosome 9 is greenkemias and solid tumors, but the gene in 8q13 is 
unknown [20]. Band 7p22 in patient 1 correspond-
ed to the map location of common fragile sites [21]. 
Among the 6 presented patients, 3 had simple 
and 3 had complex variant Ph translocations. To the 
best of our knowledge only a few cases of variant 
Ph translocations involving >3 chromosomes have 
been reported [1,5,9,11-19,22,23]. In all, 2 of the pre-
sented patients (4 and 6) had 4-way rearrangement 
[t(1;9;22;3)(q24;q34;q11;q21)  and  t(4;8;9;22)
(q11;q13;q34;q11)], including breakpoints that dif-
fered from those previously reported. CML studies 
reported 1q24 and 3q21 in simple and 3-way variant 
Ph  translocations  [8,20].  The  literature  does  not 
contain  any  reports  of  4-way  complex  transloca-
tions involving the chromosomal band 1q24 in CML 
patients. Similarly, simple and complex variant Ph 
translocations involving chromosomal bands 4q11 
and  8q13  have  not  yet  been  reported  in  CML 
patients. In CML patients 8q13 has been reported in 
translocations other than Ph and 4q11 was reported 
in association  with ANLL [8,18,20]. Specific chro-
mosomal abnormalities involving band 3q21 have 
been observed in all FAB subtypes of acute myeloid 
leukemia  (AML),  in  myelodysplastic  syndrome, 
occasionally in the blastic phase of chronic myeloid 
leukemia, and rarely in chronic phase CML. 
In some older studies variant Ph translocations 
involving 3q21 were considered a marker of poor 
prognosis  in  CML,  and  were  used  to  justify  the 
necessity  of  increasing  the  dose  of  imatinib,  as 
commonly administered in the accelerated phase 
[24]. Patient 4 in the present study did not have a 
hematological or cytogenetic response to imatinib. 
Consequently, imatinib was replaced by dasatinib, 
which was administered for 1 year, but also did not 
result in a cytogenetic or hematological response. 
Excluding patient 3, all the presented patients with 
variant Ph translocations were poor responders to 
imatinib and were therefore treated with dasatinib. 
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Table 3. Chromosomes involved in variant Ph translocations in the 6 patients and previously reported breakpoints
Chromosomes seen in our cases  Type of translocations reported in the literature  Reference 
4p14, 14q32  t(4;14;9;22)(p14;q32;q34;q11)  Aoun et al. 2004 [1] 
6q25, 8q22  t(6;8;9;22)(q25;q22;q34;q11)  Acar et al. 1997 [9]
1p36  t(1;9;22)(p36;q34;q11) 
3p25  t(3;9;22)(p25;q34;q11)  Yehuda et al. 1999 [5]
4p14  t(4;9;22)(p14;q34;q11)
12q22  t(9;22;12)(q34;q11;q22) 
7q22  t(7;9;22)(q22;q34;q11)  Zagariaa et al. 2004 [4]
8q12  t(8;9;22)(q12;q34;q11) 
3q26  t(3;9;22)(q26;q34;q11) 
4p14  t(4;9;22)(p14;q34;q11)  Morel et al. 2003 [10]
4p16  t(4;9;22)(p16;q34;q11) 
6p22, 12q13  t(6,9;12;22)(p22;q34;q13;q11)  Zagariaa et al. 2006 [11]
1q36  t(1;22)(q36;q11) 
4q31  t(4;9;22)(q31;q34;q11)
7q12  t(7;9;22)(q31;q34;q12)  Zang et al. 1993 [12]
12q24.1  t(9;22;12)(q34;q11;q24.1)
3q26.2, 17q21  t(3;17;9;22)(q26.2;q21;q34;q11)
1p36  der(1)t(1;9;22)(p36.1;q34;q11.2)
1q42  t(1;9;22)(q42; q34;q11.2)
7q11.2  der(9;22;7)ins(7;22)(q11.2;q11q.12)
  t(9;22;7)(q34;q11.2;q11.2) 
Reddy et al. 2000 [13]
12p13  t(9;22;12)(q34;11.2;p13)
15q15, 21q11.2  t(9;22;15;21)(q34;q11.2;q15;q11.2)
1q25, 20q13, 1p35  t(1;20;9;22;1)(q25;q13;q34;q11.2; p35) The  strongest  evidence  for  serial  stepwise  rear-
rangements resulting in variant Ph translocation comes 
from the rare observation of patients with a standard Ph 
in 1 clone and a complex variant Ph in another clone, 
as in patient 4 in the present study, who had 1 clone 
with t(9;22)(q34;q11) and 1 clone with a complex vari-
ant  Ph  translocation  t(1;9;22;3)(q24;q34;q11;q21). 
Cytogenetic evidence suggests that complex Ph trans-
location is derived from simple Ph translocation [17,25].
The breakpoints of variant Ph translocations in 
CML patients may be important, as they are associ-
ated with carcinogenesis. Above all, monitorization 
of chromosomes and localization of precise break-
points involved in the complex rearrangements in 
CML patients will improve our understanding of the 
genetic mechanisms that play a role in the progres-
sion of malignant disease. We trust that the present 
study’s results will contribute to the scientific com-
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Table 3. Continued
Chromosomes seen in our cases  Type of translocations reported in the literature  Reference 
1p36  t(1;9;22)(p36.1;q34;q11.2) 
1q21  t(1;9;22)(q21;q34;q11.2)
12p13  t(9;22;12)(q34;q11.2;p13)  Costa et al. 2006 [14]
12q13  t(9;22;12)(q34;q11.2;q13)
12p13, 20q12  t(9;22;20;12)(q34;q11.2;q12;p13)
1p36  t(1;9;22)(p36;q34;q11) 
3p11  t(3;9;22)(p11;q34;q11)
3q12  t(3;9;22)(q12;q34;q11)  Markovic et al. 2000 [15]
4q12  t(4;9;22)(q12;q34;q11)
1p36,11p15q23  t(1;11;22)(p36.2;p15q13;q12),  Babicka et al. 2006 [16]
4q34  t(4;9;22)(q34;q34;q11) 
1p36  t(1;9;22)(p36;q34;q11)
1q32  t(1;9;22)(q32;q34;q11)
1q42  t(1;9;22)(q42;q34;q11)
3p21  t(3;9;22)(p21;q34;q11)
3q21  t(3;22)(q21;q11)
4p14  t(4;9;22)(p14;q34;q11)
4p16  t(4;22)(p16;q11)
4q31  t(4;9;22)(q31;q34;q11)
7q11  t(7;9;22)(q11;q34;q11)
7q32  t(7,9,22)(q32;q34;q11)  Reid et al. 2003 [17]
12p12  t(12;22)(p12;q11)
12q13  t(9;22;12)(q34;q11;q13)
12q14  t(9;22;12)(q34;q11;q14)
15q15  t(9;22;15)(q34;q11;q15)
15q15  t(15;22)(q15;q11)
15q24  t(9;22;15)(q34;q11;q24)
5q13,7q11  t(5;7;9;22)(q13;q11;q34;q11)
6q24, 8q24  t(6;9;22;8)(q24;q34;q11;q24)
7q22,15q14  t(7;9;22;15)(q22;q34;q11;q14) 
4q12  t(4;22)(q12;q11)  Baxter et al. 2002 [18]
4q25  t(4;9;22)(q25;q34;q11)  Sheth et al. 2005 [19]
Note. The same breakpoints with ours that involved in variant Ph translocations in literature were marked by bold charactermunity’s knowledge of CML cytogenetics. Written 
informed consent was obtained from all the patients.
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